BPC-157 vs TB-500

What is BPC-157

BPC-157 is a synthetic chain of fifteen amino acids, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, derived from a partial sequence of a protein identified in human gastric juice; BPC stands for body protection compound. Researchers isolated this fragment because it is unusually resistant to degradation in gastric fluid. Laboratory research in cell and animal models has examined its interaction with angiogenesis and growth-factor signalling pathways such as those involving VEGF. Formula C62H98N16O22, 1419.5 g/mol, CAS 137525-51-0.

What is TB-500

TB-500 is a synthetic peptide reproducing the actin-binding region of thymosin beta-4, a naturally occurring 43-amino-acid protein found across many cell types. Thymosin beta-4 binds monomeric G-actin and holds a pool of it in reserve, influencing where and how quickly actin filaments assemble; because filament dynamics underlie how a cell changes shape and moves, TB-500 is studied in cell-migration and cytoskeletal-remodelling work using scratch-wound assays and time-lapse microscopy. Formula C38H68N10O14, 889.0 g/mol, CAS 885340-08-9.

Key differences

From products.ts, the guides and the library's classification fields:

• Origin - BPC-157 from a gastric juice protein sequence; TB-500 from thymosin beta-4, a cellular actin-binding protein
• Length - BPC-157 is fifteen residues; TB-500 is a fragment of a 43-residue parent protein
• Primary mechanism studied - BPC-157: angiogenesis and growth-factor signalling; TB-500: actin binding and cytoskeletal remodelling
• Typical research setting - BPC-157: cell and animal models of tissue-level signalling; TB-500: cell culture models of cell migration
• Mechanism label - BPC-157: synthetic pentadecapeptide used in peptide-signalling research; TB-500: thymosin beta-4 fragment studied for actin and cytoskeletal dynamics
• Amount and pens - both at 15mg per 3ml cartridge in WOLVERINE, GLOW and KLOW
• Status - both regulated compounds, both preclinical literatures

Which Celyfe pen carries them

Both peptides are in all three combination pens, always at 15mg each. The WOLVERINE Pen is the pair on its own, co-formulated 1:1 in 3ml at 10mg/ml, 30mg in total and 0.100mg per click. The GLOW Pen adds GHK-Cu (75mg) for 105mg and 0.350mg per click, and the KLOW Pen adds KPV (15mg) on top for 120mg and 0.400mg per click. The WOLVERINE product page describes the pair as the control-arm formulation for GLOW and KLOW study designs.

All three are on sale now, alongside the NAD+ Precision Pen. The published WOLVERINE certificate (batch C26071) is a third-party HPLC report on a sample Celyfe supplied: 99% purity for each peptide, with a measured content of about 91% of label for BPC-157 and 85% for TB-500. All Celyfe pens ship pre-mixed and cold-chain, are refrigerated at 2 to 8 °C on arrival, must not be frozen. Third-party HPLC certificates are published for the NAD+ and WOLVERINE pens; GLOW and KLOW certificates are being re-issued. Every Celyfe pen is supplied and labelled for laboratory research use. Nothing on this page is guidance on use in humans or animals.

How they fit together

The guide to the WOLVERINE Pen explains why the market pairs them: they come from different origins and are studied through different mechanisms, but both appear in the literature on cell migration and tissue-signalling processes. A laboratory comparing single versus combined activity runs them as a pair.

Pairing them in one cartridge is a formulation convention, not evidence that the combination has been studied as a distinct entity; each compound's literature should be read on its own terms. The WOLVERINE product page links three references, listed under sources.

Related comparisons

GHK-Cu vs BPC-157 covers the compound the GLOW Pen adds to this pair. WOLVERINE Pen vs GLOW Pen and GLOW Pen vs KLOW Pen compare the devices. BPC-157 vs Thymosin Alpha-1 sets BPC-157 beside a peptide Celyfe does not carry.